Regulation of Rat Pulmonary Artery Endothelial Cell Transforming Growth Factor-beta Production by IL-1 Beta and Tumor Necrosis Factor-alpha
Overview
Affiliations
Recent studies suggest that transforming growth factor-beta (TGF-beta) production is up-regulated at sites of tissue injury, inflammation and repair, or fibrosis. Endothelial cells represent a potentially important in vivo source of TGF-beta; however, the identity of endogenous modulators of TGF-beta production by these cells remains unclear. To address this issue, the effects of the cytokines, IL-1 beta, and TNF-alpha on TGF-beta production by rat pulmonary artery endothelial cells were examined. Conditioned media from cells treated with 0 to 20 ng/ml IL-1 beta and/or TNF-alpha were assayed for TGF-beta activity using a mink lung epithelial cell line. The results show that rat pulmonary artery endothelial cells secreted undetectable amounts of active TGF-beta in the absence of cytokines. However, upon acidification of the conditioned media before assay, a time-dependent increase in TGF-beta activity was noted in media from both untreated and cytokine-treated cells. However, both IL-1 beta and TNF-alpha treatment caused the secretion of significantly greater amounts of TGF-beta activity than control cells, in a dose-dependent manner, with maximal response obtained at cytokine doses of greater than 10 ng/ml. At equivalent doses of cytokine tested, the magnitude of the response was significantly greater with IL-1 beta. These responses were paralleled by increases in steady state mRNA levels for TGF-beta 1. Addition of both cytokines resulted in a synergistic response. Synergism with IL-1 beta was also noted with the fibrogenic agent bleomycin. Kinetic studies indicated that a minimum of 4 h of treatment with either IL-1 beta or TNF-alpha was required for detection of significant increases in either secreted TGF-beta activity or steady state TGF-beta 1 mRNA levels. Thus, endothelial cells could play a role in various TGF-beta-dependent processes in vivo, in situations wherein IL-1 beta and/or TNF-alpha may be present at comparable concentrations.
Pain improvement in Camurati-Engelmann disease after anti-TNFα therapy.
Moreira S, Cunha B, Jesus N, Santos L BMJ Case Rep. 2017; 2017.
PMID: 29184006 PMC: 5720334. DOI: 10.1136/bcr-2017-221760.
Huang T, Lai H, Ko Y, Ojcius D, Lan Y, Martel J Sci Rep. 2015; 5:15282.
PMID: 26497260 PMC: 4620496. DOI: 10.1038/srep15282.
Gao H, Fisher P, Lambi A, Wade C, Barr-Gillespie A, Popoff S PLoS One. 2013; 8(8):e71875.
PMID: 24015193 PMC: 3756034. DOI: 10.1371/journal.pone.0071875.
Martino R, Coelho A, Kubrusly M, Leitao R, Sampietre S, Machado M World J Gastrointest Surg. 2012; 4(6):146-51.
PMID: 22816029 PMC: 3400043. DOI: 10.4240/wjgs.v4.i6.146.
IL-1β promotes TGF-β1 and IL-2 dependent Foxp3 expression in regulatory T cells.
Ganesh B, Bhattacharya P, Gopisetty A, Sheng J, Vasu C, Prabhakar B PLoS One. 2011; 6(7):e21949.
PMID: 21779356 PMC: 3136935. DOI: 10.1371/journal.pone.0021949.